• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.

作者信息

De Lepeleire I, Van Hecken A, Verbesselt R, Kaiser G, Barner A, Holmes I, De Schepper P J

机构信息

Department of Pharmacology, University of Leuven, Medical School, Belgium.

出版信息

Eur J Clin Pharmacol. 1988;34(5):465-8. doi: 10.1007/BF01046703.

DOI:10.1007/BF01046703
PMID:3203706
Abstract

Single oral doses of 10 mg converting enzyme inhibitor benazepril (CGS 14824A) and 40 mg furosemide were administered to 12 healthy male volunteers either separately or concomitantly. The pharmacokinetic parameters of benazepril were not influenced by coadministration of furosemide. Urinary excretion of total furosemide was significantly reduced by 10 to 20% in the presence of benazepril. This effect was considered clinically insignificant. Erect blood pressure decreased and pulse rate increased only during concomitant treatment.

摘要

相似文献

1
Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.
Eur J Clin Pharmacol. 1988;34(5):465-8. doi: 10.1007/BF01046703.
2
The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers.阿司匹林与血管紧张素转换酶抑制剂贝那普利在健康志愿者中不存在药代动力学相互作用。
Biopharm Drug Dispos. 1994 Aug;15(6):451-61. doi: 10.1002/bdd.2510150603.
3
The pharmacokinetics of benazepril relative to other ACE inhibitors.
Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. doi: 10.1002/clc.4960141807.
4
Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.在健康马匹中静脉注射和口服苯那普利后,苯那普利和贝那普利拉的药代动力学/药效学建模。
Res Vet Sci. 2017 Oct;114:117-122. doi: 10.1016/j.rvsc.2017.03.016. Epub 2017 Mar 28.
5
Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
Biopharm Drug Dispos. 1989 Jul-Aug;10(4):365-76. doi: 10.1002/bdd.2510100404.
6
Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.贝那普利、罗贝考昔及其联合用药对猫肾小球滤过率的影响。
BMC Vet Res. 2016 Jun 23;12(1):124. doi: 10.1186/s12917-016-0734-4.
7
Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects.苯那普利与氨氯地平在健康受试者中的药代动力学相互作用研究。
Eur J Clin Pharmacol. 1994;47(3):285-9. doi: 10.1007/BF02570510.
8
Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects.
J Clin Pharmacol. 1988 Sep;28(9):848-52. doi: 10.1002/j.1552-4604.1988.tb03227.x.
9
Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.正常犬中呋塞米激活的肾素-血管紧张素-醛固酮系统中贝那普利引发的醛固酮突破现象
J Vet Pharmacol Ther. 2015 Feb;38(1):65-73. doi: 10.1111/jvp.12154. Epub 2014 Sep 16.
10
The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride.
Biopharm Drug Dispos. 1990 Dec;11(9):753-64. doi: 10.1002/bdd.2510110903.

引用本文的文献

1
Pharmacokinetic drug interactions with ACE inhibitors.与血管紧张素转换酶抑制剂的药代动力学药物相互作用。
Clin Pharmacokinet. 1993 Jul;25(1):20-58. doi: 10.2165/00003088-199325010-00003.
2
Effects of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection.
Clin Investig. 1993 Aug;71(8):622-7. doi: 10.1007/BF00184489.
3
ACE inhibitors. Drug interactions of clinical significance.血管紧张素转换酶抑制剂。具有临床意义的药物相互作用。
Drug Saf. 1995 May;12(5):334-47. doi: 10.2165/00002018-199512050-00005.

本文引用的文献

1
The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.使用高效液相色谱法来阐明速尿及其代谢产物的代谢和尿排泄情况。
Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):223-9. doi: 10.1111/j.1600-0773.1981.tb00897.x.
2
An aid to decision-making in bioequivalence assessment.
J Pharmacokinet Biopharm. 1981 Apr;9(2):235-43. doi: 10.1007/BF01068085.
3
Comparison of different methods for decision-making in bioequivalence assessment.生物等效性评估中不同决策方法的比较。
4
Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide.不同血管紧张素转换酶抑制剂对呋塞米和氢氯噻嗪利尿作用的干扰。
Klin Wochenschr. 1989 Nov 17;67(22):1138-46. doi: 10.1007/BF01726115.
5
Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects.
Eur J Clin Pharmacol. 1990;39(2):113-5. doi: 10.1007/BF00280042.
6
Clinical pharmacokinetics of the newer ACE inhibitors. A review.新型血管紧张素转换酶抑制剂的临床药代动力学。综述。
Clin Pharmacokinet. 1990 Sep;19(3):177-96. doi: 10.2165/00003088-199019030-00003.
7
Newer ACE inhibitors. A look at the future.新型血管紧张素转换酶抑制剂。展望未来。
Drugs. 1990 Dec;40(6):800-28. doi: 10.2165/00003495-199040060-00004.
8
Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.抗高血压药物的代谢产物。其临床药代动力学及治疗意义的最新综述。
Clin Pharmacokinet. 1991 Nov;21(5):331-43. doi: 10.2165/00003088-199121050-00002.
9
Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.
Drugs. 1991 Sep;42(3):511-39. doi: 10.2165/00003495-199142030-00008.
10
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.血管紧张素转换酶(ACE)抑制剂治疗的药代动力学优化
Clin Pharmacokinet. 1992 May;22(5):375-84. doi: 10.2165/00003088-199222050-00004.
Biometrics. 1981 Jun;37(2):213-22.
4
Implications of intraindividual variability in bioavailability studies of furosemide.速尿生物利用度研究中个体内变异性的影响。
Eur J Clin Pharmacol. 1984;27(5):595-602. doi: 10.1007/BF00556898.
5
Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor.依那普利(MK-421)对利尿剂诱发的继发性醛固酮增多症和低钾血症的逆转作用:一种新型血管紧张素转换酶抑制剂。
Metabolism. 1983 Jul;32(7):711-6. doi: 10.1016/0026-0495(83)90129-4.
6
Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry.
J Chromatogr. 1987 Aug 7;419:123-33. doi: 10.1016/0378-4347(87)80272-4.
7
Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
Clin Pharmacol Ther. 1987 May;41(5):580-6. doi: 10.1038/clpt.1987.75.
8
Absence of a pharmacokinetic interaction between enalapril and frusemide.依那普利与速尿之间不存在药代动力学相互作用。
Br J Clin Pharmacol. 1987 Jan;23(1):84-7. doi: 10.1111/j.1365-2125.1987.tb03013.x.
9
Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.转化酶抑制剂CGS 14824A对正常志愿者的血流动力学及药理学效应
Eur J Clin Pharmacol. 1985;28(3):267-72. doi: 10.1007/BF00543322.
10
Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.卡托普利与马来酸依那普利:降压及激素效应比较
J Cardiovasc Pharmacol. 1985;7 Suppl 1:S12-5.